These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 35972444)

  • 1. Combined
    Wu J; Zhang X; Jia Z; Zhou X; Qi R; Ji H; Sun J; Sun C; Teng Z; Lu G; Chen X
    Mol Pharm; 2022 Sep; 19(9):3405-3411. PubMed ID: 35972444
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Wu J; Wang S; Zhang X; Teng Z; Wang J; Yung BC; Niu G; Zhu H; Lu G; Chen X
    J Nucl Med; 2018 Dec; 59(12):1809-1816. PubMed ID: 29700127
    [No Abstract]   [Full Text] [Related]  

  • 3.
    Wu J; Tian J; Zhang Y; Ji H; Sun J; Wang X; Sun C; Wang L; Teng Z; Lu G; Zhu H; Chen X
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2869-2876. PubMed ID: 35138445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
    Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.
    Koo HR; Park JS; Kang KW; Cho N; Chang JM; Bae MS; Kim WH; Lee SH; Kim MY; Kim JY; Seo M; Moon WK
    Eur Radiol; 2014 Mar; 24(3):610-8. PubMed ID: 24097303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes.
    Kim JY; Lee SH; Kim S; Kang T; Bae YT
    Eur Radiol; 2015 Apr; 25(4):1172-81. PubMed ID: 25298170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of preoperative
    Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
    Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer.
    Miyake KK; Nakamoto Y; Kanao S; Tanaka S; Sugie T; Mikami Y; Toi M; Togashi K
    AJR Am J Roentgenol; 2014 Aug; 203(2):272-9. PubMed ID: 25055259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Clinical Molecular Typing of Breast Invasive Ductal Carcinoma Using
    Zhang J; Liu Y; Fan H; Wang W; Shao W; Cao G; Shi X
    Acad Radiol; 2023 Sep; 30 Suppl 2():S82-S92. PubMed ID: 36624021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between ¹⁸F-FDG uptake and molecular subtype of breast cancer.
    Kitajima K; Fukushima K; Miyoshi Y; Nishimukai A; Hirota S; Igarashi Y; Katsuura T; Maruyama K; Hirota S
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1371-7. PubMed ID: 25947575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between semiquantitative PET parameters and molecular subtypes of breast invasive ductal carcinoma.
    Chiacchio S; Evangelista L; Alsharif A; Manca G; DI Martino F; Negri A; Tredici M; Cervino AR; Puccini G; Filidei E; Ghilli M; Naccarato AG; Roncella M; Volterrani D
    Q J Nucl Med Mol Imaging; 2018 Mar; 62(1):101-111. PubMed ID: 26329496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer.
    Arslan E; Çermik TF; Trabulus FDC; Talu ECK; Başaran Ş
    Nucl Med Commun; 2018 Jul; 39(7):680-690. PubMed ID: 29893750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The correlation of
    Qu YH; Long N; Ran C; Sun J
    Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtype-Guided
    Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
    Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
    Jung NY; Kim SH; Choi BB; Kim SH; Sung MS
    World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
    Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
    Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.